

FORM 51-102F3

MATERIAL CHANGE REPORT

1. **Name and Address of Issuer:**

Aurora Spine Corporation (the "Company")
1930 Palomar Point Way, Suite 103
Carlsbad, California, 92008

2. **Date of Material Change:**

September 17, 2021.

3. **News Release:**

The news release was issued and disseminated on September 20, 2021 and subsequently filed on SEDAR.

4. **Summary of Material Change:**

The Company announced that it had closed its previously announced private placement offering (the "Private Placement"). Under the Private Placement, the Company issued 11,220,930 common shares (the "Common Shares") and 8,415,697 warrants to purchase common shares (the "Common Warrants") at a combined purchase price of \$0.58 per Common Share and associated Common Warrant, for aggregate gross proceeds of approximately \$6,508,139.40.

5. **5.1 – Full Description of Material Change:**

Each Common Share and associated Common Warrant was issued at a combined purchase price of C\$0.58. Each Common Warrant entitles the holder thereof to purchase one Common Share at an exercise price of C\$0.75 per share at any time prior to the three-year anniversary of the closing date of the Private Placement (the "Closing Date").

The net proceeds of the Private Placement are expected to be used for sales, marketing, research and development and working capital requirements.

A.G.P./Alliance Global Partners (the "Agent") acted as the exclusive placement agent for the Private Placement in the United States. The Company paid a cash commission in the amount of C\$455,569.76 to the Agent, being 7.0% of the aggregate gross proceeds of the Private Placement. In addition, the Company issued to the Agent 561,046 broker warrants, being equal to 5.0% of the number of Common Shares sold under the Private Placement ("Broker Warrants"). Each Broker Warrant entitles the holder thereof to purchase one Common Share at an exercise price of C\$0.58 per share at any time prior to the three-year anniversary of the Closing Date.

No securities were offered for sale or sold in Canada.

6. **Reliance on subsection 7.1(2) of National Instrument 51-102:**

Not applicable.

7. **Omitted Information:**

No significant facts remain confidential in, and no information has been omitted from, this report.

8. **Executive Officer:**

For further information, please contact David Meyer, VP, Legal and Operations, at (760) 424-2004.

Date of Report:

September 20, 2021.